Wuhan YZY Biopharma Co., Ltd. (YZYBIO-B) reported no change in either authorised or issued share capital for the month ended 30 April 2026, according to its latest monthly return filed with the Hong Kong Stock Exchange on 6 May 2026.

Authorised / registered capital • Ordinary shares stand at 193.85 million shares of RMB 1.00 par value, comprising 179.48 million H shares and 14.37 million domestic shares. • No increase or decrease was recorded during the month.

Issued share capital • Total issued H shares remained at 179.48 million; domestic shares held steady at 14.37 million. • The company confirmed compliance with the exchange’s 25% minimum public-float requirement.

Share-based incentives • Under the 2024 H Share Option Plan, 1.25 million options were outstanding at 30 April 2026, unchanged from the prior month. • During April, option activity generated the right to issue up to 312,500 new H shares, leaving 18.13 million shares available for future grants under the scheme. • No warrants, convertible securities, or other share-issuance agreements were in place.

Treasury shares • The company held no treasury shares and reported no movements for the month.

Corporate governance • The filing was authorised by Joint Company Secretary Zheng Jianhua.

With stable share capital and a modest option overhang, YZYBIO-B’s equity structure remained unchanged in April, while maintaining regulatory compliance with Hong Kong’s public-float rules.